De-Escalating Bone-Modifying Therapy Safe, Effective in Metastatic Breast CancerDe-Escalating Bone-Modifying Therapy Safe, Effective in Metastatic Breast Cancer
(MedPage Today) — BERLIN — Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be safe in prostate cancer…
Breastfeeding causes a surge in immune cells that could prevent cancerBreastfeeding causes a surge in immune cells that could prevent cancer
Breastfeeding seems to cause specialised immune cells to flood into the breasts and stay there for years or even decades, reducing the risk of cancer
New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancerNew generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.
Protective immune cells in breastfeeding women identified as guard against breast cancer, new research findsProtective immune cells in breastfeeding women identified as guard against breast cancer, new research finds
Patients who had more cells had better outcomes, particularly for aggressive types such as triple-negative breast cancerIn the 18th century, physicians noticed nuns had some of the highest rates of breast cancer. It was one of the earliest clues that led scientists to suspect that child-bearing and breastfeeding could protect against the disease.Modern data has confirmed the centuries-old observation but the biological reasons behind it have remained unclear. Explanations have often focused on pregnancy-related hormonal changes, but research published Tuesday in Nature has found breastfeeding provides long-lasting immune protection. Continue reading…
ADC improves outcomes in advanced triple-negative breast cancer patients ineligible for immune checkpoint inhibitorsADC improves outcomes in advanced triple-negative breast cancer patients ineligible for immune checkpoint inhibitors
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.
New blood-based biomarkers could help predict bariatric surgery outcomes in teensNew blood-based biomarkers could help predict bariatric surgery outcomes in teens
A USC-led team has developed an innovative way to predict blood pressure outcomes after bariatric surgery that outperforms the current standard practice. In 108 adolescents who underwent bariatric surgery, the researchers used blood tests taken before the procedure to predict which patients would have improved blood pressure five years later. The study is one of the first to use cutting-edge “omics” techniques, which analyze the body’s small molecules and proteins, to predict long-term health outcomes.
Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast CancerTrastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast Cancer
(MedPage Today) — BERLIN — The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different HER2-positive early-stage breast cancer settings in back-to-back randomized clinical trials.
In…
STAT+: At ESMO, AstraZeneca, Gilead square off in triple-negative breast cancerSTAT+: At ESMO, AstraZeneca, Gilead square off in triple-negative breast cancer
AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about which drug may be better.
How cutting lipids could starve breast cancerHow cutting lipids could starve breast cancer
Researchers found that triple-negative breast cancer cells are “addicted” to lipids, a feature tied to obesity. By studying mice, they discovered that high lipid levels alone accelerate tumor growth. Lowering these fats slowed cancer progression, suggesting that lipid-lowering treatments could help. The findings also caution against high-fat diets such as keto for patients with obesity.
First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast CancerFirst Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer
(MedPage Today) — BERLIN — For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall survival (OS) in high-risk early breast cancer, data reported here showed.
Patients who received…